Steven Lo photoSteven Lo

President and Chief Executive Officer

Steven Lo is our Chief Executive Officer and member of the board of directors.  Steve was previously the chief commercial officer at Puma Biotechnology where he built the commercial operations infrastructure and team to launch the company’s first product, NERLYNX®, in the United States while leading the execution of global licensing agreements for rest of world. Previously, he was senior vice president and chief commercial officer at Corcept Therapeutics. At Corcept, Mr. Lo formed the commercial organization to launch the company’s first product, Korlym®, an endocrine specialty medication for a rare orphan disease (Cushing’s syndrome) and also was responsible for the corporate strategy and development of the company’s oncology franchise. Earlier in his career, he spent 13 years at Genentech in increasingly responsible roles in market access, sales and marketing, ultimately serving as franchise head, Endocrinology. He started his career in the pharmaceutical industry at AstraZeneca after holding roles in finance and operations at Kaiser Permanente. Mr. Lo holds a master’s in health administration from the University of Southern California and a B.S. in microbiology from the University of California, Davis.

Christine Matthews photoChristine Matthews

Chief Financial Officer

Christine Matthews has served as our Chief Financial Officer, responsible for Finance, Accounting, Tax and Treasury, since May 2020 and as VP and Corporate Controller of the Company since January 2019. She has over 20 years of broad leadership experience in finance and accounting. Prior to joining Zosano, she served as an accounting and financial consultant with RGP, a professional services company. Her past positions include Senior Director of Financial Planning & Analysis at Cepheid, a leading molecular diagnostic company (acquired by Danaher), supporting North America commercial operations, as well as Group Director of Finance at Cadence Design Systems. Ms. Matthews began her career with Arthur Andersen, LLP and holds a B.S. in Business Administration with an Emphasis in Accounting from the University of Colorado at Boulder.

Hayley Lewis photoHayley Lewis

Senior Vice President, Operations

Hayley Lewis serves as our Senior Vice President of Operations, where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Operations and Engineering, Manufacturing, and Regulatory Affairs, and continues to be responsible for overseeing all regulatory interactions with the FDA and other government agencies. Hayley joined the company as the Vice President of Regulatory Affairs and Quality in October 2015. Prior to joining Zosano, Hayley spent over 11 years in Regulatory Affairs at Depomed, Inc., a specialty pharmaceutical company, where she was involved in the approval of 3 commercial products. Over the course of her career, she has enabled 8 investigational products to be studied in humans, 5 of which have advanced to completion of Phase 3 trials. Hayley’s pharmaceutical development experience, spanning over 20 years, covers solid oral dosage forms, and combination products such as systemic and local inhalation products, a single entity combination injectable, and transdermal systems. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business.

Donald Kellerman photoDonald Kellerman, PharmD

Vice President, Clinical Development and Medical Affairs

Dr. Kellerman has served as our Vice President of Clinical Operations since July 2015. Prior to joining Zosano, Dr. Kellerman served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) for five years. Dr. Kellerman also held the position of Senior Vice President of Development at Inspire Pharmaceuticals, Inc. for nine years, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. In addition, Dr. Kellerman has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor, Inc., and E.R. Squibb and Sons, Inc. He has more than 25 years of experience in the development of prescription pharmaceuticals and has lead- or co-authored more than 80 publications. Dr. Kellerman holds Doctor of Pharmacy and Bachelor of Science degrees from the College of Pharmacy at the University of Minnesota.